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G protein-coupled receptors are allosteric proteins that control transmission of external signals to regulate cellular
response. Although agonist binding promotes canonical G protein signalling transmitted through conformational changes,
G protein-coupled receptors also interact with other proteins. These include other G protein-coupled receptors, other
receptors and channels, regulatory proteins and receptor-modifying proteins, notably receptor activity-modifying proteins
(RAMPs). RAMPs have at least 11 G protein-coupled receptor partners, including many class B G protein-coupled
receptors. Prototypic is the calcitonin receptor, with altered ligand speciﬁcity when co-expressed with RAMPs. To gain
molecular insight into the consequences of this protein–protein interaction, we combined molecular modelling with
mutagenesis of the calcitonin receptor extracellular domain, assessed in ligand binding and functional assays. Although
some calcitonin receptor residues are universally important for peptide interactions (calcitonin, amylin and calcitonin gene-
related peptide) in calcitonin receptor alone or with receptor activity-modifying protein, others have RAMP-dependent
effects, whereby mutations decreased amylin/calcitonin gene-related peptide potency substantially only when RAMP was
present. Remarkably, the key residues were completely conserved between calcitonin receptor and AMY receptors, and
between subtypes of AMY receptor that have different ligand preferences. Mutations at the interface between calcitonin
receptor and RAMP affected ligand pharmacology in a RAMP-dependent manner, suggesting that RAMP may allos-
terically inﬂuence the calcitonin receptor conformation. Supporting this, molecular dynamics simulations suggested that the
calcitonin receptor extracellular N-terminal domain is more ﬂexible in the presence of receptor activity-modifying protein 1.
Thus, RAMPs may act in an allosteric manner to generate a spectrum of unique calcitonin receptor conformational states,
explaining the pharmacological preferences of calcitonin receptor-RAMP complexes. This provides novel insight into our
understanding of G protein-coupled receptor-protein interaction that is likely broadly applicable for this receptor class.
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Introduction
G protein-coupled receptors (GPCRs) are essential
proteins for cell signalling. They reside at the cell sur-
face and interact with numerous factors [1]. These
include extracellular constituents such as their ligands,
integral membrane components including other
GPCRs or GPCR accessory proteins and intracellular
proteins, the most well known being G proteins.
The propensity for GPCR function to be altered by
allosteric mechanisms is substantial. Any factor that
interacts with a GPCR has the potential to inﬂuence its
conformation, and thus affecting its behaviour. This
can include interactions with ligands or a second pro-
tomer in a receptor dimer [2]. With GPCRs being
major targets for therapeutics, a profound under-
standing of the probable outcomes of such interactions
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on endogenous ligand and drug actions, both desired
and undesirable, is needed.
The propensity for GPCRs to oligomerize offers
opportunities to consider the impact of other
membrane proteins on GPCR pharmacology [2]. The
interpretation of such studies is often complicated by
the inherent ability of each protomer to interact with
ligand in its own right. However, there are GPCR
accessory proteins that can offer novel insight into
how membrane proteins alter GPCR pharmacology.
A notable example of such proteins is the family of
receptor activity-modifying proteins (RAMPs) [3].
There are three RAMPs, which each contains a
structured extracellular N-terminal domain (ECD),
a single transmembrane-spanning domain and a short
intracellular C-terminus [4]. The key interactions
between the RAMP and GPCR can reside in the N
terminus or the transmembrane domain, depending on
the speciﬁc GPCR partner for the RAMP [5, 6]. Such
interactions affect GPCR properties such as altering
pharmacology or signalling in a GPCR-speciﬁc
manner. Eleven RAMP-interacting GPCRs have
been identiﬁed to date with explicit pairings of only
certain RAMPs with some of these GPCRs [3, 6–12],
Figure 1 RAMPs modulate receptor function. (a) The CTR alone is a high-afﬁnity receptor for CT, but in the presence of RAMP1,
RAMP2 or RAMP3 is a high-afﬁnity receptor for amylin. The RAMP1/CTR complex (AMY1 receptor) has high afﬁnity for amylin
and CGRP, while the RAMP2/CTR (AMY2 receptor) and RAMP3/CTR (AMY3 receptor), are high-afﬁnity amylin receptors with
lower afﬁnity for related peptides. (b) Schematic representation showing how RAMPs are allosteric proteins that control GPCR
behaviour. In particular, RAMPs alter the accessibility of the CTR extracellular domain-binding groove to amylin and CGRP. The
afﬁnity of CTR for these ligands is modiﬁed by the binding of RAMP. In CTR alone, amylin/CGRP interactions are suboptimal.
RAMP alters the CTR-binding-site sufﬁciently to allow more optimal binding conditions. The diagram also shows how RAMPs
have broader scope as allosteric proteins, with potential for altering GPCR properties via the transmembrane bundle
and intracellular C-terminus, in addition to the ECD. G proteins are reported to inﬂuence RAMP-GPCR pharmacology, and
RAMP-GPCR complexes may also inﬂuence G protein coupling. Thus, there is likely to be multidirectional allostery, which can
explain the broad effects of RAMPs on numerous GPCRs, from pharmacology through to signalling and intracellular trafﬁcking.
(c) Crystal structure of the CGRP receptor ECD (CLR/RAMP1) with CGRPanalog ([D31, P34, F35]CGRP27-37, red) bound and
selected class B GPCR ligands: CRF (orange), adrenomedullin (AM) (green), GIP (salmon), PTH (cyan) superimposed.
(d) Homology model of the AMY1 receptor ECD (CTR/RAMP1), with residues within the putative peptide-binding site that were
selected for Ala mutation shown as red sticks.
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The largest cluster of GPCRs with which RAMPs
interact reside within the ‘B’ class of peptide-
binding GPCRs.
Like RAMPs, these GPCRs are characterized by a
structured ECD of ~ 150 amino acids that forms a
characteristic fold [13]. This GPCR ECD is the key
domain for high ligand binding and interacts with the
C-terminal portion of the natural peptide ligands for
these receptors.
The best characterized interaction of RAMPs and a
GPCR is the calcitonin receptor (CTR)-like receptor
(CLR), where individual RAMPs co-expressed with
CLR yield distinct receptors: calcitonin gene-related
peptide (CGRP) receptors and adrenomedullin recep-
tors. However, oligomerization of CLR with RAMPs
is prerequisite for functional expression of the GPCR
at the cell surface. In contrast, most other RAMP
partners can be functionally expressed in the absence
of RAMPs.
The CTR is a notable example of a RAMP-
interacting class B GPCR that is functionally expres-
sed in the absence of RAMPs. CTR acts as a receptor
for three hormones—calcitonin (CT), amylin and
CGRP with a spectrum of afﬁnities depending on its
co-expression with RAMPs. Although CTR alone is a
receptor for CT that is involved in bone homeostasis,
CTR in complex with RAMP1-3 forms the AMY1-3
receptors (Figure 1a) [14], which are high-afﬁnity
receptors for amylin, a peptide involved in the
regulation of food intake. The AMY1 receptor is also
a high-afﬁnity receptor for the neuropeptide CGRP
[7, 15] (Figure 1a).
Recently, structures of the CGRP receptor (CLR
+RAMP1) and the AM1 receptor (CLR+RAMP2)
ECDs bound to a CGRP analogue ([D31, P34, F35]
CGRP27-37) or AM25-52, respectively, were determined
[16]. These structures revealed a unique mode of
peptide binding without the α-helical structure
observed in related class B GPCR ECD structures
[17–21]. CGRP and AM instead are largely
unstructured and feature a β-turn structure near the
C-terminus enabling the C-terminal aromatic residue
to form contacts with the RAMP (Figure 1). However,
as RAMP co-expression is prerequisite for CLR
expression and function, it provides only limited insight
into how RAMPs modify the receptor to allow novel
ligand pharmacology.
Unlike CLR, the CTR is functionally expressed
at the cell surface in the absence of RAMPs. The
well-deﬁned pharmacology of CTR-RAMP complexes
makes it an ideal system to probe how RAMP
interaction enables novel GPCR function. We have
investigated the role of CTR ECD residues in peptide–
ligand interactions in the absence and presence of
each RAMP. Mutagenesis, supported by modelling,
reveals a common mode of peptide binding with the
CLR-RAMP complexes but also suggests a role for
allostery in RAMP-driven peptide selectivity via
increasing conformational ﬂexibility of the CTR ECD
(Figure 1).
Results
Peptide interactions with the CTR ECD in the absence
of RAMPs
Peptide binding to class B GPCR ECDs involves
residues located within loops 2, 4 and 5 and the
N-terminal α-helix of the ECD (Figure 1c) [22]. There
are currently no structures of the CTR ECD available.
Therefore, a homology model of the CTR ECD was
produced based on the crystal structure of the CGRP
receptor (Figure 1d). Ala mutagenesis was used to
investigate the role of the CTR ECD residues that
comprise the putative peptide-binding site (Figure 1d).
The function of all the receptor mutants was
characterized by cAMP assay, and cell surface
expression measured by ELISA. Human CT (hCT)
binding was measured at selected mutants through
competition with 125I-hCT. We used the insert-negative
form of CTR, which is named CT(a) [14]. For all
mutations, there was minimal impact on cell surface
expression of the receptor (Supplementary Table S1).
Ala mutation of selected residues in loops 2, 4 and 5
of the CTRECD (W79, F99, D101, F102, H121,W128
and Y131) signiﬁcantly reduced hCT potency and
125I-hCT binding (Figure 2a and b, Table 1 and
Supplementary Figures S1 and S2A). In contrast, Ala
mutation of residues G44, R45 and M48 within the
N-terminal α-helix did not have any effect on hCT
potency.
Having deﬁned key residues for hCT binding in the
CTR ECD, we next questioned whether lower afﬁnity
peptide ligands for CTR would require the same
complement of residues. For amylin, W79A, F102A
and Y131A had signiﬁcantly reduced potency. R126A,
which did not affect hCT potency, reduced amylin
potency by approximately threefold (Figure 2d and e,
Table 1 and Supplementary Figure S2B). Notably, two
key residues for hCT (D101 and W128) did not affect
amylin potency when mutated to Ala (Figure 2d,
Table 1 and Supplementary Figure S2B). For CGRP,
there were small reductions in potency at W79A,
F99A, D101A, F102A, H121A, W128A and Y131A
(Table 1). For both amylin and CGRP, the magnitude
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of effect of the mutation (apart from Y131A) was
always smaller than that observed for hCT (Table 1
and Supplementary Figure S2A and B). Thus, while the
pocket utilized by amylin and CGRP was substantially
the same, only weak interactions were observed and
these were conﬁned to a subset of residues. The reduced
impact of these mutations is consistent with the lower
afﬁnity of these ligands for CTR [14].
RAMPs alter the role of CTR ECD residues in
peptide–ligand binding
The AMY1 receptor complex (CTR/RAMP1) binds
both amylin and CGRP with high afﬁnity, while the
human AMY3 receptor (CTR/RAMP3) is also a high-
afﬁnity receptor for amylin but has lower afﬁnity for
CGRP [23]. At the AMY2 receptor (CTR/RAMP2),
there is only a weak enhancement in amylin and CGRP
potency compared with the CTR, depending on the
cell background and CTR splice variant [23–25].
Therefore, RAMP subtype can have a differential
effect on pharmacology. The same set of residues
initially tested at CTR expressed alone was also
investigated in the presence of RAMP1. A subset of
these was also tested with RAMP2 and RAMP3 to
determine generalities in the mode of peptide binding
to each subtype of AMY receptor.
Intriguingly, in the presence of RAMP1, the CTR
residues required for high hCT potency at the CT(a)
were important for the enhanced potency of amylin
and CGRP at the AMY1(a) receptor. Mutation of W79,
F99, D101, F102, H121, R126, W128 and Y131 to Ala
each reduced potency of both peptides (Figure 2d and f,
Table 2 and Supplementary Figure S2). 125I-hαCGRP
binding was also abolished (Supplementary
Figure S1D). In all cases, the magnitude of effect was
greater at the AMY1(a) receptor versus CT(a). Notably,
D101A and W128A, mutations that did not affect
amylin potency at CTR alone, reduced both amylin
and CGRP potency more than 50-fold in the presence
of RAMP1 (Table 1 and Figure 2d and f). The
Figure 2 Effect of predicted binding-site residue mutations on CT(a) or AMY1(a) receptor function. (a–c) The effect of mutation on
hCT-mediated responses at either the CT(a) (a, left-hand panel; b) or AMY1(a) (a, right-hand panel; c) receptor. (d–f) The effect of
mutation on rAmy (rat amylin) -mediated responses at either the CT(a) (d, left-hand panel; e) or AMY1(a) (d, right-hand panel; f)
receptor. Homology models of the isolated CTR (blue) (b, e) or the CTR/RAMP1 complex (c, f) (CTR, blue; RAMP1, pink).
Mutated residues are displayed in x-stick and CPK and coloured according to the magnitude of effect of mutation on peptide
function (red, 450-fold decreased potency; orange, 10–50-fold decreased potency; yellow, o10-fold decreased potency; and
blue, not signiﬁcantly different). Data points are mean± s.e.m., combined from four to six independent experiments, performed in
duplicate or triplicate; and displayed as change in potency of the peptide (pEC50).
Allosteric effects of RAMPs
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mutations generally had similar effects at the AMY2(a)
and AMY3(a) receptors (Supplementary Tables S2 and
S3), although the magnitude of loss of peptide potency
was generally less at AMY2(a) compared with the other
two amylin receptors, in parallel with the weaker
induction of Amy potency seen with RAMP2. For
CGRP, which has highest potency at the AMY1(a)
receptor, the D101A, F102A and W128A mutations
had profound effects on potency in the presence of
RAMP1, but not RAMP2 or RAMP3 (Supplementary
Tables S2 and S3), suggesting that the allosteric mod-
ulation of these residues provides differentiation in
CGRP interaction. R126A was without effect at
AMY2(a).
RAMP1 association with CTR, as measured by the
presence of RAMP1 at the cell surface, was assessed for
all CTR mutants (Supplementary Table S1). R126A
resulted in lower RAMP1 cell surface expression of
~ 30%. This was matched by lower CTR expression to a
similar degree, indicating that the reduced RAMP1
expression was most likely due to decreased CTR
expression and thus less RAMP1 translocation to the
cell surface, as oppose to diminished RAMP1 associ-
ation with CTR. CTR cell surface expression was
unchanged with any other mutant when expressed with
RAMP1. We also examined RAMP2 expression with
selected CTR mutants. Only R126A resulted in
decreased expression, again paralleled with decreased
CTR expression. We were unable to measure RAMP3
expression due to the absence of a suitably tagged
version that behaves like wild-type (WT) RAMP3.
Nevertheless we measured CTR mutant expression
with RAMP3 and found no changes (Supplementary
Table S1).
To determine whether the presence of RAMP
affected the hCT binding site in CTR, hCT potency at
the CTR mutations in the AMY1(a) receptor was
determined. The effects mirror those observed for CTR
alone (Figure 2a and c and Supplementary Table S4),
most likely because these responses are generated
Figure 3 Homology models of the AMY1 receptor ECD (CTR, off-white surface; RAMP1, pink surface) in complex with rAmy (rat
amylin, light blue) (a), or CGRPanalog [D31,P34, F35]CGRP27-37 (dark blue) (b), illustrating the predicted mode of peptide binding at
the AMY1 receptor. The surfaces of key residues mutated in the current study are highlighted according to the magnitude of effect
of mutation on peptide function (red, 450-fold decreased potency; orange, 10–50-fold decreased potency; yellow, o10-fold
decreased potency; and blue, not signiﬁcantly different). (c and d) illustrate how the peptides interact with the peptide-binding
groove. Receptor residues are in off-white x-stick, RAMP1 residue W84 is in orange and the peptides are blue. Peptide amino
acid numbers are displayed as superscript and receptor numbers in normal type. Hydrogen bonds are illustrated as coloured
spheres. (c) rAmy (rat amylin). (d) CGRP analogue.
Allosteric effects of RAMPs
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through CTR that is uncomplexed with RAMP, which
is consistent with a population of ‘free’ CTRs [23].
Modelling amylin and CGRP interactions with the
AMY1 ECD
To help interpret our data, we modelled amylin and
CGRP analogue interactions with the AMY1 receptor
ECD using the structure of the CGRP analogue bound
to the CGRP receptor ECD as a template (PDB ID:
4RWG) (Figure 3). There is a considerable sequence
conservation between the two peptides (Supplementary
Figure S3) and this is reﬂected by the binding modes
predicted from the models. The proposed peptide-
binding site is formed between loops 2, 3 and 5 of the
CTR ECD and RAMP1 residue W84, with the
N-terminal region of the (truncated) peptide located in
proximity to loop 4. Both CGRP and amylin contain
an aromatic residue at the C-terminus (Phe in CGRP,
Tyr in amylin) and the hydrophobic interaction
between the aromatic C-terminal residue of the peptide
and the RAMP1 residue W84 is apparently conserved
(Figure 3c and d). CTR residue D101 forms hydrogen
bonds with T30 of the peptides in our models. Receptor
residues W79, F99, F102 and Y131 that form the core
of the binding site make hydrophobic interactions with
the peptide (Figure 3c and d). Residues H121, R126
and W128 in loop 5 of the CTR ECD form contacts
with the β-turn structure of the CGRP analogue
(Figure 3d). Thus the models suggest that the key
peptide interactions with the CLR ECD are conserved
with the CTR ECD and therefore it is unclear what
drives peptide selectivity between the CLR and
the CTR.
Residue differences between receptor sequences in the
peptide-binding site do not contribute to peptide
selectivity between CTR and CLR
There are, however, several residues within or in
proximity to the peptide-binding site that differ
between the CTR and CLR (Supplementary
Figures S3A and S4). To investigate whether residue
differences at these positions contribute to peptide
selectivity, CTR residues at these positions were
mutated to the equivalent residue in the CLR: G44T,
P100Q, E123A, N124S and S129T. If these residues
contributed to selectivity, the mutants would be
expected to result in reductions in hCT and amylin
potency because CLR has very low afﬁnity for these
ligands [14, 15]. At the CT(a) and AMY1(a) receptors,
none of these mutants affected hCT, amylin or
CGRP (Supplementary Table S5 and Supplementary
Figure S4), suggesting that the residue differences
between the CLR and CTR ECDs do not contribute to
peptide selectivity between the two receptors.
Mutation of interface residues between CTR and
RAMP1 and dynamics of the complex
The lack of any obvious mechanism for peptide
speciﬁcity directly within the peptide-binding site,
coupled with the differences observed in the role of
residues D101 andW128 between the CTR and AMY1
receptor, led us to question whether RAMPs act
allosterically to inﬂuence the role of residues within
CTR. To test this, we hypothesized that altering the
RAMP-CTR interface could affect amylin and CGRP
potency. Amino acid sequence alignment and model-
ling suggested that CTR had a similar interaction
interface with RAMP1 to that observed for CLR,
Figure 4 Effect of mutation on predicted CTR/RAMP1 interface residues. Homology model of the isolated CTR (blue) (a) or the
CTR/RAMP1 complex (CTR, blue; RAMP1, pink) (b). Insets are graphs of the change in rAmy (rat amylin) cAMP potency (pEC50)
at either the CT(a) (a) or AMY1(a) (b) receptors compared with WT. Mutated residues (Q52, Y53 and Y56 in CTR, and Y66, H97
and F101 in RAMP1) are displayed in x-stick and CPK and coloured according to the magnitude of effect of mutation on peptide
function (orange, 10–50-fold decreased potency; yellow, o10-fold decreased potency; and blue, not signiﬁcantly different). Data
points are mean± s.e.m., combined from four to six independent experiments, performed in duplicate or triplicate.
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involving residues along the N-terminal helix of the
ECD (Figures 1d and 4). Mutation of Q52, Y53 and
Y56 to Ala did not affect hCT or amylin potency in
CTR alone but resulted in signiﬁcant decreases in
amylin and CGRP potency at the AMY1(a) receptor
(Figure 4, Supplementary Figure S5 and Table 3).
Q52A resulted in a modest reduction in potency, while
larger effects were observed with Y53A and Y56A.
Interestingly, these mutations substantially reduced
125I-CGRP binding, even though these residues are
not part of the peptide-binding site (Figure 1c).
Cell-surface expression was unaffected with all of these
mutations, suggesting that any disruption in the
interface between CTR and RAMP was not sufﬁcient
to affect the amount of receptor at the cell surface
(Supplementary Table S1). A similar pattern of
RAMP-dependency was observed with these muta-
tions at RAMP3 but not RAMP2-based receptors
(Supplementary Tables S2 and S3).
We next examined the effects of interface mutations
in RAMP1 by mutating the conserved RAMP residues
Y66, H97 and F101. Each mutation resulted in sig-
niﬁcant decreases in amylin and CGRP potency and
CGRP binding (Figure 4, Supplementary Figures S1
and S5 and Table 3). There was a greater reduction in
CGRP potency in comparison to amylin, suggesting
that disruption of the interface can have ligand-
dependent effects. However, there were also sig-
niﬁcant reductions in cell surface expression, which
may partially account for the loss of amylin and CGRP
potency (Supplementary Table S6), though not the
differences between the peptides.
To investigate whether RAMP1 inﬂuences the
conformation of the CTR ECD, extended molecular
dynamics simulations were performed. The association
of RAMP1 with CTR produces signiﬁcant changes
in the structure and dynamics of the latter in our
simulations (Figure 5).
With the exception of loop 1, during a 1 μs
molecular dynamics simulation, the CTR structure is
relatively stable in the absence of RAMP1, suggesting
that the binding pocket has limited ﬂexibility. By
contrast, after association with RAMP1, loops 4 and
5 and particularly the C-terminus of the CTR
model become much more dynamic (Figure 5). The
C-terminus undergoes a complex, writhing movement
leading to considerable displacement of residues from
R126 to Y131 (Figure 5c). This was analysed by
principle component analysis and it was found that the
majority of the movement (60%) could be described
by the ﬁrst eigenvector (Supplementary Figure S6),
although the same pattern was observed in all of theTa
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ﬁrst ten eigenvectors (Supplementary Figure S6).
The movement was maintained over the majority of the
entire 1 μs simulation (Supplementary Figure S6).
The movements in loops 4 and 5 are consistent with the
modelling of peptide binding to the AMY1(a) receptor,
with a predicted lateral extension and closure of the
binding pocket associated with movement of loop 5
residues that likely facilitates interaction between the
peptide C-terminus and the RAMP1 residue (W84)
(Figure 5c and d versus Figure 5e and f). Similarly, the
orientation of residues in loop 4, which are critical for
high peptide potency, are also altered in models
of peptide-bound receptors, whereas the key loop 2
residue (W79) is effectively unaltered in the model of
amylin binding (Figure 5c). Because of the dynamic
changes in the C-terminus there does not seem to be a
single stable structure for this part of the CTR model,
at least during the course of the simulation. The
mechanism for the change may be the close proximity
of the helix 2/3 loop of RAMP1 to loop 5 of the CTR
ECD. In particular, this destabilizes the structure
of loop 5 and C-terminus leading to the increased
ﬂexibility seen in the simulation. This ﬂexibility in turn
may be exploited by amylin and CGRP, allowing them
to form better contacts than can be made with CTR
alone when it is in a rigid state.
Discussion
GPCRs are natural allosteric proteins that propa-
gate extracellular signals to modulate intracellular
signalling. Many GPCRs exist in protein complexes,
including as homo- and hetero-GPCR dimers/
oligomers as well as forming other protein–protein
interactions with other classes of receptors, and various
scaffolding, trafﬁcking and modulating proteins. Most
of these interactions lead to altered receptor function
through formation of novel binding interfaces or
by allosterically modulating GPCR function [2].
Nonetheless, we have only very limited molecular
understanding of how these protein–protein interac-
tions change receptor function.
As exemplar GPCR modulating proteins, with at
least 11 GPCR partners, and a broad array of effects
Figure 5 The RAMP1 ECD inﬂuences the dynamics of the CTR ECD. (a) Comparison of RMSF of the principle eigenvector for
CTR alone and in complex with RAMP1. (b) Movement of the cα atoms of the CTR alone (red) with CTR (blue) in complex with
RAMP1 (pink) showing the midpoint and extreme ﬂuctuations of the principle eigenvector. (c) X-stick representation of the key
residues for peptide binding for the CTR alone (blue) or in the presence of RAMP1 (pink), with W84 of RAMP in off-white.
Residues in loop 5 (H121, R126 and W128) and in loop 2 (F99, D101 and F102) are substantially displaced when RAMP1
interacts with the receptor, and this is consistent with the MD simulations. (d–f) display the reorganization of the surface of the
peptide-binding pocket; (d) CTR alone; (e) CTR in the presence of RAMP1; and (f) CTR in the presence of RAMP1 displaying the
modelled amylin peptide (blue).
Joseph J Gingell et al.
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from altering cellular trafﬁcking to engendering novel
ligand pharmacology [3, 6–12], understanding of
RAMP action provides insight into the spectrum of
effects arising from protein-GPCR interaction. In
the current study, we demonstrate that RAMPs
allosterically alter the CTR N-terminal domain to
enable high-afﬁnity binding to amylin and CGRP
peptides.
Recent advances in structural biology have provided
important insights into the allosteric mechanism link-
ing agonist binding to G protein activation, with this
allosteric transition being driven by ordered changes in
conserved hydrogen-bonded polar networks within the
GPCR, leading to thermodynamically reciprocal
changes in conformation of the intracellular surface of
the receptor and to the ligand-binding pocket [26–28].
Of note, relatively small changes in the binding pocket,
as are observed in the β2-adrenoceptor, can link to
large changes in the intracellular face of the receptor
that interacts with effector G proteins [29].
Similarly, although there is only limited structural
information available, the allosteric cooperativity
between small molecule modulators and orthosteric
ligands is thought to principally occur via coupled
conformational changes, although other factors such as
electrostatic attraction or repulsion can also inﬂuence
the interaction of spatially linked ligands [30].
Intriguingly, in the current study, the allosteric effect
of RAMP on the ECD appeared to be principally
driven by increased entropy in key loop regions of the
ECD, in particular loop 5 and to a lesser extent loop 4.
This was evident in the molecular dynamic simulations,
with a high degree of correlation between the predicted
increased ﬂexibility of residues in these loops and the
altered position of these residues in models of amylin
peptide docking (Figure 5). Such entropically driven
allostery is consistent with our evolving understanding
of protein–protein allostery, where a range of allosteric
mechanisms are now recognized, including the well-
studied coordinated, ordered alteration to binding
sites, as occurs for GPCR-effector coupling, but also
includes entropically driven changes that increase
protein ﬂexibility, as well as ordered to disordered
transitions [31, 32]. Thus, it is apparent that binding
interactions can be affected by the interchange between
protein stability and ﬂexibility in transforming protein
conformational landscapes, and that global dynamics
and not just local interactions can modify surface
properties of the protein to allosterically regulate
responses, as reviewed by [31–33].
The recent solution of crystal structures of the pep-
tide bound ECD of the CLR and RAMP1 or RAMP2
revealed that CGRP and AM have a distinct binding
mode to other class B peptides and have limited sec-
ondary structure in complex with the receptor/RAMP
N-terminal domain complex; they form interactions
principally with loop regions of the receptor ECD in
addition to a single important contact with the RAMPs
via the peptide C-terminus [16]. This contrasts with
other class B receptor/ligand complexes where an
extended peptide α-helix is observed that interacts with
the receptor N-terminal α-helix, in addition to loop
contacts, although there is overlap in positioning of the
CGRP/AM peptides and CRF (Figure 1c). Unlike
CTR, CLR requires RAMP co-expression to enable
peptide binding. The CTR alone has high afﬁnity for
CT peptides but low afﬁnity for amylin and CGRP.
Mutagenesis revealed a conserved binding pocket for
all 3 peptides in both CTR alone and when complexed
with RAMP, but the relative contribution of residues
was markedly different between CTR alone and
with RAMP.
Of the residues impacting on peptide function only
R126 contributed to amylin or CGRP function but not
that of CT. R126 in the CTR/RAMP complex sits in
close proximity to W84 (RAMP1) that may form an
interaction with the peptide C-terminus for amylin and
CGRP, and thus may contribute to the orientation
of the peptide C-terminus to allow this interaction.
The net contribution of the RAMP interaction is a
reordering of residues in loop 5 that facilitates the
peptide turn of amylin and CGRP and interaction of
the C-terminus with the W84 of the RAMP, with
reorientation of loop 4 residues facilitating interactions
between the receptor ECD and the peptide (Figure 5).
In particular, modelling of peptide binding to the
receptor suggests that both amylin and CGRP form an
H-bond between T30 of the peptide and D101 of the
receptor, while V32 contacts a hydrophobic patch
comprised of W79, F102 and Y131 (Figure 3c). An Ala
scan of an amylin analogue supports our models,
with T30 and V32 substitutions abolishing binding.
Interestingly, mutation of C-terminal Y37 had little
effect on binding [34].
While CGRP has high afﬁnity and potency at both
AMY1 and CGRP receptors, only the AMY1 receptor
has high afﬁnity for amylin. The key residues for
CGRP binding to both receptors are conserved
between CTR and CLR, and these residues are also
critical for amylin binding to the AMY1 receptor.
To try to understand the selectivity difference we also
mutated the non-conserved residues between CTR and
CLR, however, these were not important for peptide
potency/selectivity. Thus, the basis for peptide
Allosteric effects of RAMPs
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selectivity between the CGRP and AMY1 receptor
cannot be readily explained by non-conserved inter-
actions and is difﬁcult to rationalize purely based on
the N-terminal domain structures of the receptor
complexes.
Although it is difﬁcult to rationalize the selectivity
differences between amylin and CGRP at the CGRP
receptor without further experimentation, our data
provides potential insight into the basis of selectivity of
different RAMP/CTR complexes for CGRP. The three
AMY receptors have similar afﬁnity for amylin but
only the AMY1 receptor has high afﬁnity for CGRP.
For amylin, the magnitude of effect of individual
amino acid mutations was similar for different
CTR/RAMP complexes, implying a similar allosteric
effect on key residues to enable higher afﬁnity binding.
In contrast, the magnitude of effect on CGRP potency
was greater for three of the residues, W128, D101 and
F102 and the differential impact of these residues on
CGRP interaction likely accounts for the higher
potency of CGRP for the CTR/RAMP1 complex. Our
previous studies using RAMP1/RAMP2 chimeras
revealed that the short intracellular C-terminus of the
RAMP plays a critical role in the higher potency of
CGRP for AMY1 versus AMY2 receptors [35]. Thus,
long-range allosteric effects are also important for the
observed peptide interactions with the receptor ECD.
Mutation of the interface between CTR and RAMP1
had more dramatic effects on CGRP than on amylin
potency, suggesting that these long-range allosteric
effects nonetheless are, at least in part, transmitted via
the extracellular RAMP/CTR interface. Previous work
has implicated the RAMP C-terminus in AMY
receptor-effector coupling, particularly for G protein-
dependent signalling [36], and it is therefore likely that
it is the ternary complex of the receptor with effector
protein that allosterically differentiates between amylin
and CGRP binding. For CGRP and AM signalling,
efﬁciency of G protein coupling (at least for Gs) is
dependent upon the intracellular accessory protein,
receptor component protein [37]. It is plausible that this
difference could contribute to the selectivity difference
for amylin between CGRP and AMY1 receptors.
RAMPs acting allosterically to determine CTR
ligand selectivity is further supported by examining
how RAMPs alter the conformation of the related
CLR as evident in crystal structures of the CGRP
analogue-bound CLR:RAMP1 and AM-bound CLR:
RAMP2 ECD complexes [16]. A molecular morph
between the two structures was generated to assess how
RAMPs alter CLR conformation (Supplementary
Movie S1). Although the morph does not represent a
true physical pathway between conformational states,
it is nonetheless useful for visualizing conformational
change. The morph highlights movement of CLR α1 as
well as shifts in several side chains on CLR α1 at the
interface with the RAMPs. These changes appear to
be propagated to the peptide-binding site in CLR
resulting in subtle, yet likely signiﬁcant changes to the
shape of the peptide-binding site. RAMP1 and -2
clearly elicit different conformational states of CLR,
which likely contributes to selectivity for CGRP or
AM. It is conceivable that binding of RAMPs to the
CTR N-terminal α-helix induces or stabilizes con-
formations of CTR that changes the peptide-binding
site to better accommodate amylin and CGRP.
This study reveals that entropically driven allosteric
effects have a role to play in GPCR based, protein–
protein interactions. Furthermore, selectivity differ-
ences between different RAMP-CTR complexes for
CGRP appeared to be driven by long-range allosteric
interactions that are likely to involve interaction of
intracellular effector proteins with the C-terminal
domain of RAMPs, but that are nonetheless
transmitted, at least in part, via the extracellular
interface between the RAMP and the receptor ECD
(Figure 1b). This work provides novel insight into how
protein interactions modulate GPCR function.
Materials and Methods
Peptides
Rat amylin and hCT were purchased from American
Peptide; human αCGRP was made in-house [38] or purchased
from American Peptide. Peptides were made up as 1 mM
stock solutions with ultrapure water and stored in siliconized
microfuge tubes at − 20 °C. Radioiodination of hCT was
performed by adding 200 μCi of NaI (PerkinElmer, Waltham,
MA, USA) to 20 μg of hCT and incubating with an iodination
bead (Pierce) for 5 min. I125 labelled hCT was then puriﬁed using
reverse-phaseHPLC, using a C18 column (Phenomenex, Torrance,
CA, USA). 125-I-CGRP was purchased from PerkinElmer. The
pharmacology of both radioligands was conﬁrmed
(Supplementary Figure S1).
Plasmids
The double HA-tagged CTR construct used was generated as
previously described [39]. This is the insert-negative form of
the receptor and is referred to as hCT(a), to comply with Inter-
national Union of Pharmacology guidelines [40]. Myc tagged
RAMP1 and untagged RAMP3 constructs were used for AMY
receptor experiments. A RAMP2 construct with an N-terminal
FLAG tag [41] was used for AMY2(a) receptor experiments.
Receptor mutagenesis
Mutagenesis was performed based on the Quick-change II
method as previously described [42] with the following
Joseph J Gingell et al.
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modiﬁcations. Primers were purchased from Integrated DNA
Technologies Ltd (Coralville, IA, USA). Kapa HiFi readymix
(Kapa Biosystems, Wilmington, MA, USA) or Primestar HS
enzymes (TaKaRa Bio, Kyoto, Japan) were substituted for Pfu
polymerase. RAMP1 constructs Y66A, H97A and F101A were
produced as previously described [43].
Cell culture
Cos-7 and HEK293S cells were cultured using DMEM high-
glucose media (Invitrogen, Thermo Fisher, Waltham, MA,
USA) supplemented with 8% fetal bovine serum (Moregate
Biotech, Hamilton, New Zealand) in a humidiﬁed incubator at
37 °C, 5% CO2. Cells were seeded at a density of 1.5 × 10
5–
2.0× 105 cells per ml in 96-well plates. For 125I-hαCGRP
experiments Cos-7 cells were seeded at a density of 7.5 × 105 cells
per ml in 24-well plates. Cells were transfected using poly-
ethylenimine after 24 h and were grown for an additional 48 h
before assaying as described previously [42]. Equal quantities of
CTR and RAMP were used.
cAMP assay
cAMP assays were performed as previously described [44]
with the following modiﬁcations. After stimulation the reaction
was stopped by removing media and adding 50 μl per well of
ice-cold absolute ethanol. Plates were stored at − 30 °C for up to
4 days before the measurement of cAMP was performed.
The ethanol was allowed to evaporate and 40 (50 μl for
HEK293S) of lysis buffer was added to each well before shaking
for 15 min.
Radioligand binding assay
Competitive radioligand binding assay was performed
in whole cells. For 125I-hCT experiments, Cos-7 cells were
plated and transfected in 96-well plates as per cAMP assay,
for 125I-hαCGRP experiments Cos-7 cells were plated and
transfected in 24-well plates. After 48 h, cells were washed with
binding buffer (DMEM with 0.1% BSA), then incubated with
binding buffer containing ~ 50 pM 125I-hCT or 125I-hαCGRP and
increasing concentrations of unlabelled competitor peptide for
1 h at 37 °C. Cells were washed with ice-cold PBS pH 7.4 and
lysed in 0.2 M NaOH. Radioactivity was measured using a
Wizard2 gamma counter (PerkinElmer). Non-speciﬁc binding
was determined using 1 μM unlabelled hCT or hαCGRP; total
binding was established in the absence of a competitor peptide.
ELISA
Cell-surface expression was determined by ELISA and per-
formed as previously described [42]. Brieﬂy, cells were plated
and transfected as per cAMP assay. Cell-surface expression of
receptor components was detected using mouse anti HA
monoclonal antibody 1:2000 (Covance, Princeton, NJ, USA;
MMS-101P), anti-myc 1:250 (Merck Millipore, Billerica, MA,
USA; 9E10) or anti-FLAG 1:1000 (Sigma-Aldrich, St Louis,
MO, USA; F1804-1G) to detect the tagged receptors. Goat anti-
mouse biotin conjugate (Sigma-Aldrich) and Streptavidin HRP
polymer (Sigma-Aldrich) were used to detect the antibodies
using SigmaFast o-phenylenediamine dihydrochloride tablets
(Sigma-Aldrich). Data were normalized to WT receptor
transfected cells as 100% (either CTR with empty vector or
RAMP) and empty vector transfected cells as 0%. Statistical
signiﬁcance was achieved if the 95% conﬁdence interval did not
include 100%.
Homology modelling of CTR and AMY receptor ECDs
CTR and CLR full-length sequences were aligned using
Tcoffee [45]. Amultiple template design was used to generate the
CTR ECD. CLR ECD, chain A from 3N7S, was used as a
template structure for CTR ECD. The ﬁrst loop domain of
chain A (3N7S) is not elucidated. Therefore, the loop domain of
3N7S (chain B) was used as the template for this loop domain
in the CTR ECD. Modeller9v8 [46] was used to generate
500 models. The models were ranked by the Modeller9v8 energy
objective function. The top 10 structures were retained and the
stereochemical quality was assessed by PROCHECKv3.5.4.
[47]. On the basis of overall and residue-by-residue geometry a
structure was selected. The ProPka program [48] via the
PDBQPR server [49] was used to assign the protonation states of
the titratable groups in CTR ECD, using the CHARMM
parameters set at pH 7.0. The CHARMM (c35b3) module
Screened Coulomb Potentials Implicit Solvent Model was used
to minimize the model. 100 steps of steepest descent were
conducted followed by adopted basis Newton-Raphson
minimization until convergence was met.
To model CGRP and rat amylin bound to the AMY
receptor, a similar approach was used to that for the modelling
of the receptor without ligand, but the structure of a CGRP
analogue bound to the CGRP receptor ECD was used as a
template (PDB ID: 4RWG). This was mutated in-silico to give
the structures of either human CGRP or amylin. Subsequent
steps were as described above. PDB ﬁles are available as
Supplementary Material (ctr_ecd; ctr_r1; ctr-ramp1-cgrpmut;
ctr-ramp1-ramy).
Molecular dynamics
Homology models of the ECD of the CTR alone and the
CTR ECD docked to the RAMP1 ECD were based on the
CLR/RAMP1 ECD structure 3N7R using a Clustal Omega
alignment. With Modeller v9.10, 1 000 models were generated
and scored using OPUS_PSP. The best scoring model was
visually inspected before minimization using the Amber99sb
ILDN force-ﬁeld as implemented in GROMACS. For MD
simulations, the minimized protein was placed centrally in a
charge neutral cubic box (x = 10 nm) consisting of TIP3 water
molecules, 150 mM NaCl and simulated for 1 μs. Principal
component analysis of the resulting trajectories was used to
identify the main eigenvectors and the root mean square
ﬂuctuation calculated.
Data analysis and statistics
Data for cAMP accumulation assay and radioligand binding
were ﬁtted to a three-parameter logistic equation in Prism 6
(Graphpad Software, San Diego, CA, USA) to determine the
EC50 or IC50, after ﬁrst using an F-test to determine whether the
Hill-slope differed from 1. Statistical signiﬁcance was deter-
mined through unpaired t-test. In each experiment cAMP data
Allosteric effects of RAMPs
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were normalized to the ﬁtted minimum and maximum of the
WT curve on each assay plate.
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